Switzerland approves vaccine that targets two Covid variants
The Swiss medicaments regulator Swissmedic has given temporary approval for a Covid-19 vaccine from Moderna that has been adapted to give protection against two different strains of the virus.
This content was published on
1 minute
swissinfo.ch/mga
Español
es
Suiza aprueba vacuna contra dos variantes de COVID
The ‘Spikevax Bivalent Original/Omicron’ is designed to be administered in two 0.5ml doses.
It contains 25 micrograms of the original Spikevax mRNA-1273 plus 25 micrograms of a different mRNA that targets the Omicron variant (BA.1 and BA.4/5).
On Monday, Swissmedic saidExternal link that in trials the dual vaccine had achieved higher antibody concentrations against the Omicron variant than the original Spikevax, “with comparable side-effects”.
Those side-effects can include irritation, redness or swelling at the injection site, fatigue, headache, chills or nausea.
The Human Medicines Expert Committee has also given its separate seal of approval for the new vaccine, said Swissmedic.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Swiss authorities announce cost-cutting in asylum sector
This content was published on
The government notably wants to improve integration into the labour force, particularly for people with protection status S.
Various leaders confirm participation at Ukraine peace conference
This content was published on
The presidents of Poland, Finland, and Latvia and the prime ministers of Spain and Belgium will be at the Swiss-hosted talks in mid-June.
This content was published on
In the winter season up to April 2024, railway and cable car operators ferried 3% more visitors compared to the previous winter, and 5% more than the five-year average.
Rhine flooding: Swiss to invest CHF1 billion with Austria
This content was published on
As part of an international agreement with Austria, the Swiss government wants to pump CHF1 billion ($1.1 billion) into flood protection measures along the Rhine over the next three decades.
Swiss government proposes CHF10 million UNRWA donation
This content was published on
After months of debate, Switzerland plans to give CHF10 million ($11 million) to the UN agency this year, rather than the CHF20 million initially foreseen.
Swiss study: insects mainly migrate at midday and dusk
This content was published on
A study led by the Swiss Ornithological Institute in canton Lucerne is helping to better understand the movement patterns of migratory insects.
Red Cross: 22 staff killed in Middle East since October
This content was published on
The Red Cross and Red Crescent network in Gaza and Israel has lost 22 staff members since last October, the Swiss Red Cross (SRC) said on Wednesday.
Dortmund’s Kobel is first Swiss goalie in Champions League final
This content was published on
Borussia Dortmund’s Gregor Kobel has achieved history by becoming the first Swiss goalkeeper to reach a Champion’s League final.
University students in Switzerland join Gaza protest wave
This content was published on
Pro-Palestinian activists occupied university buildings in Lausanne, Geneva and Zurich on Tuesday, widening the protest movement in the Alpine nation.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Switzerland gives green light to Moderna’s Covid vaccine for 6-11 year olds
This content was published on
The Swiss medical regulator Swissmedic has approved Moderna’s Spikevax Covid-19 vaccine for use by children aged 6 to 11 years.
Switzerland approves its first protein-based Covid vaccine
This content was published on
The Swiss medical regulator has approved the Nuvaxovid vaccine for adults making it the fourth Covid-19 vaccine authorised in the country.
Too many Covid doses: Switzerland’s vaccine conundrum
This content was published on
Switzerland is sitting on around 38 million excess Covid-19 vaccine doses to be used by the end of 2022. What will it do with them?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.